Research and development are the foundation of Verséa Pharmaceuticals. We are dedicated to the advancement and improvement of traditional prescription pharmaceuticals and hemp-derived pharmaceuticals. The goal of our research and development is to build a robust pipeline of highly qualified and characterized new chemical entities and botanical entities for advancement down a clinical pathway with the FDA.
VCX is a high throughput screening platform and process for evaluating new drug candidates (new chemical and botanical entities). After two years of development the VCX Discovery Platform is now able to study compounds of interest to assess therapeutic potential and risk in a cost-efficient high throughput manner.
The VCX Platform is a scalable system that saves millions of dollars in the drug discovery process consumed by time and poorly qualified compounds. The VCX Platform de-risks the discovery and development process by providing a means of assessing the therapeutic potential of hundreds of compounds over short periods of time, generating data in weeks, not years. With the completion of the development of the VCX Discovery Platform and filing of IP, Verséa is now begin screening hemp-derived and pharmaceutical compounds to build a pipeline of New Chemical Entities (NCEs) and Botanical Rx drug candidates. Areas of interest to Verséa include:
Our clinical program is driven by compounds emerging out of our discovery program aimed at advancing NCE and Rx Botanical candidates towards global market approvals. The initial focus of Verséa is on the prescription hemp clinical program. The near-term goal of this program is to develop and assess pipeline assets for successful Investigational New Drugs (INDs) submissions for various hemp-derived Rx botanical candidates. Verséa is positioned to a first mover in this market segment.
Verséa is the first company in the United States to fund and initiate an IRB approved patient registry tracking the real-world utilization of Verséa products. In advance of pipeline assets entering clinical development, the data generated from the registry will be first of its kind and will be published in the medical literature and utilized to support development packages submitted to FDA. To date over 300 patients have been enrolled into the registry.